NCT03317743View on ClinicalTrials.gov

Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 29, 2017

Primary Completion Date

December 8, 2020

Study Completion Date

October 13, 2021

Conditions
Advanced Solid Tumors
Interventions
DRUG

NOV140101 (IDX-1197)

The dose levels will be escalated following a 3+3 dose escalation scheme.

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

IlDong Pharmaceutical Co Ltd

INDUSTRY

collaborator

National OncoVenture

OTHER

lead

Idience Co., Ltd.

INDUSTRY

NCT03317743 - Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter